Delving into the Latest Updates on The Fourth Military Medical University of the Chinese People's Liberation Army with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Infectious Diseases

Prophylactic vaccine

Antibody drug conjugate (ADC)

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Infectious Diseases	2

Top 5 Drug Type	Count

Prophylactic vaccine	2
Antibody drug conjugate (ADC)	1
Small molecule drug	1
Monoclonal antibody	1

Top 5 Target	Count

BSG(Basigin)	2
TLR2 x TLR4	1

本研究是单中心、开放、剂量递增的Ia期临床研究，目的是考察剂量递增的美妥珠（HcHAb18）单抗注射液在标准治疗失败的非小细胞肺癌患者中的安全性、耐受性以及药代动力学特征，确定最大耐受剂量，同时初步考察美妥珠单抗的抗肿瘤活性，为后续临床研究的用药方案提供依据。

[Translation]

This study is a single-center, open-label, dose-escalating Phase Ia clinical study. Its purpose is to investigate the safety, tolerability, and pharmacokinetic characteristics of escalating doses of metuzoumab (HcHAb18) monoclonal antibody injection in patients with non-small cell lung cancer who have failed standard treatment, determine the maximum tolerated dose, and preliminarily investigate the anti-tumor activity of metuzoumab to provide a basis for the medication regimen of subsequent clinical studies.

Start Date07 Jul 2015

Sponsor / Collaborator

The Fourth Military Medical University of the Chinese People's Liberation Army

[+1]

100 Clinical Results associated with The Fourth Military Medical University of the Chinese People's Liberation Army

Login to view more data

0 Patents (Medical) associated with The Fourth Military Medical University of the Chinese People's Liberation Army

Login to view more data

100 Deals associated with The Fourth Military Medical University of the Chinese People's Liberation Army

Login to view more data

100 Translational Medicine associated with The Fourth Military Medical University of the Chinese People's Liberation Army

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Mertuzumab(Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd) ( BSG )	Non-Small Cell Lung Cancer More	Phase 1
rVSV-HTNV-GP	Hantavirus Infections More	Preclinical
HcHAb18-DM1 ( BSG )	Non-Small Cell Lung Cancer More	Preclinical
Compound 42g(University of Parma)	Neoplasms More	Preclinical
PP19128R ( TLR2 x TLR4 )	Latent Tuberculosis More	Preclinical